A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the “Back of the Line” as a therapy for dyslipidemia?

A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the “Back of the Line” as a therapy for dyslipidemia?

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Clinical Lipidology - Volume 2, Issue 5, October 2008, Pages 313-317

Peter P. MD, PhD, Kevin C. PhD,